Lv11
30 积分 2022-08-16 加入
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
1小时前
待确认
Elsevier Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
21天前
已关闭
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
26天前
已完结
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
1个月前
已完结
Synergistic Integration of mRNA-LNP with CAR-Engineered Immune Cells: Pioneering Progress in Immunotherapy
1个月前
已完结
Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration
1个月前
已完结
Diagnosis and management of neutropenia in children: The approach of the Study Group on Neutropenia and Marrow Failure Syndromes of the Pediatric Italian Hemato‐Oncology Association (Associazione Italiana Emato‐Oncologia Pediatrica ‐ AIEOP)
1个月前
已完结
Efficacy and Safety of Pegylated Filgrastim as Primary Prophylaxis Following Pediatric Dose-intensive Chemotherapy A Randomized Controlled Trial
1个月前
已完结
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia after Same-Day Dosing of Eflapegrastim in Patients with Breast Cancer Receiving Docetaxel and Cyclophosphamide (NCT04187898)
2个月前
已关闭
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
2个月前
已完结
皖公网安备34019202002308
